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Increased Levels of Soluble Vascular Cell Adhesion
Molecule 1 Are Associated With Risk of
Cardiovascular Mortality in Type 2 Diabetes 
The Hoorn Study
Agnes Jager, Victor W.M. van Hinsbergh, Piet J. Kostense, Jef J. Emeis, Giel Nijpels, Jacqueline M. Dekker,
Robert J. Heine, Lex M. Bouter, and Coen D.A. Stehouwer
Membrane-bound vascular cell adhesion molecule 1
(VCAM-1) allows the tethering and rolling of mono-
cytes and lymphocytes as well as firm attachment and
transendothelial migration of leukocytes. Soluble
forms of VCAM (sVCAM-1) may serve as monitors of
increased expression of membrane-bound VCAM-1 and
thus may reflect progressive formation of atheroscle-
rotic lesions. Levels of sVCAM-1 have been found to be
increased among type 2 diabetic as compared with non-
diabetic subjects. To study the association of plasma
sVCAM-1 concentration and risk of cardiovascular and
all-cause mortality among nondiabetic and diabetic
subjects, we investigated an age-, sex-, and glucose-tol-
erance–stratified sample (n = 631) of a population-
based cohort aged 50–75 years that was followed
p r o s p e c t i v e l y. Plasma levels of sVCAM-1 were deter-
mined in frozen –70°C baseline samples. After 7.4 years
(mean) of follow-up, 107 (17%) subjects had died
( 4 2 of cardiovascular causes). In the entire group,
increased sVCAM-1 levels were significantly associated
with increased risk of cardiovascular mortality (relative
risks [RRs] per 100 ng/ml sVCAM-1 increase, 1.10
[1.05–1.15] after adjustment for age, sex, and glucose
tolerance status). This RR was somewhat diminished by
further adjustment for the presence of hypertension
and cardiovascular disease; levels of total, HDL, and
LDL cholesterol and homocysteine; the presence of
microalbuminuria (a putative marker of endothelial
dysfunction); levels of von Willebrand factor (a marker
of endothelial dysfunction) and C-reactive protein (a
marker of low-grade inflammation); and estimates of
glomerular filtration rate. However, the RR remained
statistically significant. The RR among type 2 diabetic
subjects was 1.13 (1.07–1.20) per 100 ng/ml sVCAM-1
increase after adjustment for age and sex, which was
somewhat higher but not significantly different from the
RR in nondiabetic subjects (P value for interaction
term, 0.12). Further adjustment for other risk factors
gave similar results. In conclusion, levels of sVCAM-1
are independently associated with the risk of cardio-
vascular mortality in type 2 diabetic subjects and
therefore might be useful for identifying subjects at
increased cardiovascular risk. Increased plasma
sVCAM-1 levels may reflect progressive formation of
atherosclerotic lesions, or sVCAM-1 itself may have
bioactive properties related to cardiovascular risk. Our
data, however, argue against the hypotheses of sVCAM-1
levels simply being a marker of endothelial dysfunc-
tion, of low-grade inflammation, or of an impaired renal
function. D i a b e t e s 4 9 :4 8 5–491, 2000
A dherence of circulating leukocytes to endothe-lium and their subsequent transmigration intothe arterial intima is an early step in the forma-tion of atherosclerotic lesions (1). The recruit-
ment of leukocytes into tissues is dependent on a cascade of
events mediated through a diverse family of cellular adhesion
molecules that are expressed on the surface of vascular
endothelial cells (2,3).
Membrane-bound vascular cell adhesion molecule 1 (VCAM-1)
is expressed mainly on endothelial cells, smooth muscle cells,
and tissue macrophages (4,5) and allows the tethering and
rolling of monocytes and lymphocytes, as well as firm attach-
ment and transendothelial migration of leukocytes (6–9).
Endothelial expression of VCAM-1 occurs on human athero-
sclerotic plaques (10,11) and has been shown to be an early
manifestation of experimental cholesterol-induced athero-
sclerosis (12,13).
Soluble forms (sVCAM-1) have been detected in plasma
(14,15). Secretion of sVCAM-1 is reported to be indicative of
the expression of membrane-bound VCAM-1 (16). Although the
pathophysiological role of these soluble forms is unclear, it has
been hypothesized that sVCAM-1 levels may serve as a mon-
itor of expression of membrane-bound VCAM-1. Increased
levels thus may reflect progressive formation of atherosclerotic
lesions (14,17). In addition, recent cross-sectional studies
showed sVCAM-1 concentration to be positively associated
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with carotid artery intima-media thickness (18—20) and with
the severity of peripheral arterial disease assessed by angiog-
raphy (18,21). In prospective studies, however, high levels of
sVCAM-1 could not be demonstrated to be associated with risk
of cardiovascular events (22,23), which is in contrast with
Þndings on other adhesion molecules, such as intercellular
adhesion molecule 1 and E-selectin (22,24).
Most (20,25—29), but not all (30,31), studies have shown
sVCAM-1 levels to be increased among type 2 diabetic sub-
jects as compared with nondiabetic subjects, and sVCAM-1
levels have been shown to be independently associated with
carotid artery intima-media thickness in type 2 diabetes
patients (29). In view of these considerations, we investi-
gated the association of sVCAM-1 concentration and risk of
cardiovascular and all-cause mortality among nondiabetic
and type 2 diabetic subjects in a prospective, population-
based cohort study.
RESEARCH DESIGN AND METHODS
General study design. The study population consisted of an age-, sex-, and glu-
c o s e - t o l e r a n c e – s t r a t i fied sample of the Hoorn Study, a population-based cohort
study of disturbances of glucose tolerance in a Caucasian population aged 50–75
years conducted from October 1989 to February 1992, which has been described
previously (32,33). Briefly, 2,484 Caucasian subjects (71% of those invited) partic-
ipated. All subjects, except previously diagnosed diabetic subjects treated with oral
glucose-lowering agents or insulin, underwent an oral glucose tolerance test
(OGTT) according to the World Health Organization guidelines (33). Subjects
with a 2-h postload glucose ‡7.5 mmol/l, all subjects with type 2 diabetes, and a ran-
dom sample of subjects with a 2-h postload glucose <7.5 mmol/l stratified by age
and sex were invited within 4 weeks for a second visit to investigate glucose-intol-
erance–related complications (709 were invited, of whom 631 [89%] participated).
These subjects underwent a second OGTT (except those who already used glucose-
lowering agents; n = 67). On the basis of the mean of the two OGTTs, glucose tol-
erance was divided into three categories (32,33): normal glucose tolerance (n = 288),
impaired glucose tolerance (n = 170), and type 2 diabetes (n = 173). Subjects with
normal or impaired glucose tolerance or type 2 diabetes in the present study pop-
ulation thus represented a stratified random sample of all subjects with normal or
impaired glucose tolerance or type 2 diabetes in the initial cohort. Because the exact
sampling procedure is known, we can back-calculate the prevalences of glucose
tolerance categories and of associated variables, such as ischemic heart disease,
in the initial cohort (n = 2,484) from those in the second sample (n = 631) by “direct
standardization,” as previously described in detail (32,33).
From these subjects, we obtained an ankle-brachial blood pressure index
(n = 631) and a resting electrocardiogram (n = 625 [32,33]). Subjects were clas-
s i fied as having cardiovascular disease when they had a history of myocardial
infarction; had an electrocardiogram with a Minnesota code 1.1–1.3, 4.1–4.3,
5.1–5.3, or 7.1; had undergone coronary bypass surgery or angioplasty; had an
ankle-brachial pressure index <0.9 in either leg; and/or had undergone a periph-
eral arterial bypass or amputation.
s V C A M - 1 . Baseline concentrations of sVCAM-1 were assessed in deep-frozen
(–70°C) heparin plasma samples. The mean duration of storage was 8.3 years
(range 7.3–9.4). No plasma was available for 21 subjects. Concentrations of
sVCAM-1 were measured in duplicate by enzyme-linked immunosorbent assay
(ELISA) kits (Bender MedSystems, Wenen, Austria [Cat. #BMS232]); reference
plasma values in 111 healthy subjects, as provided by the manufacturer, are 1,090
( 2 3 7 ng/ml; range 675–1,693). We measured sVCAM-1 levels in 27 healthy volunteers
and found a mean level of 966 ng/ml. The mean variation between duplicate
plasma samples in the assay was 3.4%. The interassay variation is 14%. To limit
experimental variation, all samples of the study were assayed simultaneously, in
duplicate, on the same day. For comparability with other studies, it should be noted
that the same pooled plasma contained 471 ng/ml sVCAM-1 when assayed by the
Amersham (Buckinghamshire, U.K.) sVCAM-1 kit and 416 ng/ml when assayed by
the Biosource (Nivelles, Belgium) sVCAM-1 kit.
Other measurements. We obtained data on blood pressure, weight, height,
BMI, and smoking habits (32,33). Hypertension was defined as diastolic pressure
‡ 9 5 mmHg, systolic pressure ‡160 mmHg, and/or the use of antihypertensive drugs
(33). Current smoking was defined as currently smoking cigarettes and/or cigars.
We also obtained data on plasma GHb; fasting insulin, serum creatinine, homo-
cysteine, total cholesterol, HDL cholesterol, and triglyceride levels; and urinary
albumin and creatinine levels (32–34). Serum levels of urea nitrogen concentra-
tion were determined in samples stored at –70°C by a kinetic ultraviolet assay from
Roche Diagnostics (Mannheim, Germany). Serum albumin levels were assessed
using the bromcresol purple method. LDL cholesterol was calculated by the
Friedewald formula (33), except when triglyceride level was >4.55 mmol/l (n =
23). The glomerular filtration rate was estimated in two ways: 1) from the Cock-
roft-Gault formula for creatinine clearance (33) and 2) from the formula proposed
by the Modification of Diet in Renal Disease Study Group (MDRD formula [35]):
G F R = 170 · [serum creatinine level (mg/dl)]– 0 . 7 2 6 · [age]– 0 . 1 7 6 · [0.762 if patients is
f e m a l e ] · [1.180 if patient is black] · [serum urea nitrogen level (mg/dl)]– 0 . 1 7 0 ·
[serum albumin level (g/dl)]+ 0 . 3 1 8. Microalbuminuria was defined as an albumin-
to-creatinine ratio >2.0 mg/mmol (33). Concentrations of von Willebrand factor
(vWF) and C-reactive protein (CRP) were assessed as previously described (36).
F o l l o w - u p . Data on the subjects’ vital status on 1 January 1999 were collected
from the mortality register of the municipality of Hoorn. For the 49 subjects who
had moved out of town, information on vital status was obtained from the new
local municipalities. For each subject, we determined whether or not death had
occurred during follow-up, and if so, the date at which death occurred. For all sub-
jects who died, the cause of death was extracted from the medical records of the
general practitioner and the hospital of Hoorn and classified according to the ninth
edition of the International Classification of Diseases (32,34). Cardiovascular
mortality was defined as codes 390–459 and cancer mortality as codes 140–240.
Information on cause of death could not be obtained for 16 (15%) of the deceased
subjects, and 1 subject was lost to follow-up.
All participants gave informed consent for this study, which was approved by
the local ethics committee.
Statistical analyses. All analyses were performed with SPSS 7.5 for Wi n d o w s
95. The associations between sVCAM-1 levels and cardiovascular risk factors (such
as smoking and hypertension) and risk indicators (such as microalbuminuria and
vWF and CRP levels) were tested by linear regression analyses with sVCAM-1 lev-
els (log-transformed because of a better fit of the regression model) as dependent
variable and risk factors or indicators as independent variables, all adjusted for
age, sex, and glucose tolerance status (unless this was the variable under con-
sideration). Survival over the follow-up duration was calculated by Kaplan-Meier
curves for different groups, and differences were tested by the log-rank test. To
assess associations of cardiovascular risk factors and risk indicators with risks
of cardiovascular and all-cause mortality, we performed a Cox proportional haz-
ards multiple regression analysis, in all cases—because of the stratification pro-
cedure—with adjustment for age, sex, and glucose tolerance status. Results are
described as relative risks (RRs) (hazard ratios) with 95% CIs.
Risk factors and risk indicators measured on a continuous scale were used as
such in the regression models, except for BMI and levels of HDL cholesterol, CRP,
and vWF, because the association of these variables with mortality was nonlin-
e a r. Therefore, a low level of HDL cholesterol was defined as a level <0.9 m m o l / l
(32); a high level of vWF or CRP was defined as a level in the upper tertile
( > 1 . 5 6 IU/ml and >2.84 mg/l, respectively [36]); and obesity was defined as a BMI
> 2 7k g / m2 for men and >26 k g / m2 for women (32). Levels of fasting insulin and
triglyceride were log-transformed because of a better fit of the regression model.
sVCAM-1 was entered into the regression models as a continuous variable,
because the association with mortality was linear. To assess whether the associ-
ations of sVCAM-1 with mortality were independent, regression analyses were
adjusted primarily for all variables that were statistically significantly associated
with cardiovascular mortality, except for microalbuminuria, levels of vWF and CRP,
and estimates of glomerular filtration rate; and secondarily, for variables signifi-
cantly associated with sVCAM-1 levels, or microalbuminuria (a putative marker
of endothelial dysfunction), or levels of vWF (a marker of endothelial dysfunction),
or levels of CRP (a marker of low-grade inflammation), or estimates of glomeru-
lar filtration rate. To evaluate a possible interaction between sVCAM-1 levels and
risk factors or indicators significantly associated with mortality with regard to car-
diovascular or all-cause mortality, Cox regression analyses were performed with
the risk factor or indicator of interest, sVCAM-1, their product term, and age, sex,
and glucose tolerance status in the model. A significant RR for the product term
was considered an interaction of sVCAM-1 with that risk factor or indicator.
Two-sided P values <0.05 were considered statistically signific a n t .
R E S U LT S
Ta b l e 1 (two columns on the left) shows the baseline char-
acteristics of the study population. The median (range) of
sVCAM-1 levels was 1,305 (417–5,260) ng/ml. The percentage
of subjects with a sVCAM-1 level in the highest tertile
( > 1 , 4 8 4 ng/ml) per glucose tolerance status was 27% for nor-
mal glucose tolerance, 37% for impaired glucose tolerance,
and 41% for type 2 diabetes.
The mean ± SD duration of follow-up was 7.4 ± 1.7 years,
with a range of 0.5–9.2 years. After 7.4 years of follow-up, 107
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(49 type 2 diabetic subjects) of the 631 subjects had died, of
whom 42 (39%; 21 type 2 diabetic subjects) had died of car-
diovascular disease. Subjects who died had higher levels of
sVCAM-1 than did those who survived (1,534 ± 639 vs. 1,355 ±
3 9 5 ng/ml, respectively). Ta b l e 1 (three columns on the right)
shows RRs of mortality associated with risk factors and risk
i n d i c a t o r s .
Associations of sVCAM-1 level with cardiovascular risk
factors and indicators. After adjustment for age, sex, and
glucose tolerance status (unless this was the variable under
consideration; Ta b l e 2), sVCAM-1 levels were signific a n t l y
associated with the following: male sex; age; levels of fasting
insulin, vWF, CRP, and homocysteine; and the presence of
t y p e 2 diabetes, hypertension, and microalbuminuria.
sVCAM-1 levels were inversely associated with total, LDL, and
HDL cholesterol levels, current smoking, and estimates of
glomerular filtration rate, and they were borderline signifi-
cantly associated with the presence of cardiovascular disease.
sVCAM-1 levels were not significantly associated with BMI or
levels of GHb and triglycerides after adjustment for age, sex,
and glucose tolerance status (data not shown).
sVCAM-1 level and risk of cardiovascular mortality.
Subjects with sVCAM-1 levels in the upper and the middle ter-
tiles had about a threefold and twofold increased risk of car-
diovascular mortality, respectively, as compared with subjects
with sVCAM-1 levels in the lowest tertile (Fig. 1). The test for
trend for increasing sVCAM-1 levels expressed per tertile
was significant (P = 0.04), suggesting a linear relationship.
In the entire group, sVCAM-1 levels were signific a n t l y
associated with increased risk of cardiovascular mortality
after adjustment for age, sex, and glucose tolerance status (RR
per 100 ng/ml sVCAM-1 increase, 1.10 [1.05–1.15]; Ta b l e 3 ) .
Further adjustment for the presence of hypertension, car-
diovascular disease, current smoking, microalbuminuria, lev-
els of fasting insulin, total, LDL, and HDL cholesterol, homo-
cysteine, vWF, and CRP, and estimates of glomerular fil t r a t i o n
rate slightly diminished the RRs (Ta b l e 3, first column).
Adjustment for BMI and levels of GHb and triglycerides
(added to model 2 in Ta b l e 3) did not materially change the
results (data not shown).
The RRs of cardiovascular mortality associated with
increased sVCAM-1 levels were not significantly different in
the presence as compared with the absence of type 2 diabetes
(P value for interaction term 0.12). The RRs, if anything,
seemed somewhat stronger among type 2 diabetic subjects
( Ta b l e 3). Again, adjustment for BMI and levels of GHb and
triglycerides (added to model 2 in Ta b l e 3) did not materially
change the results (data not shown).
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A. JAGER AND ASSOCIATES
TA B L E 1
Baseline characteristics and RR of cardiovascular and all-cause mortality associated with risk factors or risk indicators 
Baseline characteristics
Percentage, 
Mortality associated with the indicated difference in risk factor or indicator
mean ± SD, or RR (95% CI)
median Difference in C a r d i o v a s c u l a r All-cause 
Risk factor (interquartile range) risk factor or indicator mortality m o r t a l i t y
Male sex (%) 4 8 Yes vs. no 1.35 (0.73–2.48) 1.40 (0.95–1.93)
Age (years) 64 ± 7 Per 5-year increase 1.69 (1.29–2.24) 1.62 (1.37–1.91)
GHb (% of hemoglobin) 5.9 ± 1.3 Per 1% of hemoglobin increase 1.14 (0.93–1.42) 1.16 (1.01–1.33)
Fasting insulin (pmol/l) 84 (63–119) Per 10% increase* 1.03 (0.97–1.10) 1.03 (0.99–1.08)
Type 2 diabetes (%) 2 7 Yes vs. no 2.76 (1.35–5.65) 2.38 (1.52–3.71)
BMI (kg/m2) 27.2 ± 4.0 High vs. low† 1.91 (0.93–3.92) 1.41 (0.92–2.17)
Total cholesterol (mmol/l) 6.6 ± 1.2 Per 1.0 mmol/l increase 1.23 (0.97–1.56) 1.11 (0.96–1.30)
LDL cholesterol (mmol/l) 4.5 ± 1.1 Per 1.0 mmol/l increase 1.27 (0.97–1.65) 1.10 (0.93–1.31)
HDL cholesterol (mmol/l) 1.3 ± 0.4 Low vs. high‡ 2.74 (1.31–5.71) 1.87 (1.13–3.09)
Triglycerides (mmol/l) 1.6 (1.2–2.2) Per 10% increase* 1.06 (0.99–1.13) 1.04 (1.01–1.08)
sVCAM-1 (ng/ml) 1,305 (417–5,260) Per 100 ng/ml increase 1.10 (1.05–1.15) 1.04 (1.00–1.08)
vWF (IU/ml) 1.37 ± 0.70 High vs. low§ 1.95 (1.04–3.64) 1.67 (1.13–2.49)
CRP (mg/l) 1.75 (0.83–3.80) High vs. low§ 2.02 (1.08–3.80) 1.49 (1.00–2.21)
Homocysteine (µmol/l) 12.6 ± 5.8 Per 5 µmol/l increase 1.14 (0.99–1.31) 1.08 (0.95–1.21)
Hypertension (%) 3 9 Yes vs. no 2.79 (1.41–5.50) 1.66 (1.11–2.48)
Current smokers (%) 2 8 Yes vs. no 1.74 (0.88–3.42) 1.86 (1.23–2.81)
Microalbuminuria (%) 1 1 Yes vs. no 3.38 (1.71–6.68) 1.73 (1.05–2.84)
Creatinine clearance 78.5 ± 18.1 Per 5 ml/min increase 0.88 (0.79–0.97) 0.94 (0.88–1.01)
( m l / m i n ) ¶
Glomerular filtration rate 67.8 ± 12.1 Per 5 ml · min– 1 · 1.73 m– 2 0.72 (0.64–0.81) 0.94 (0.88–1.01)
(ml · min– 1 · 1.73 m– 2) #
Prior cardiovascular disease (%) 2 4 Yes vs. no 3.79 (2.01–7.18) 2.11 (1.42–3.14)
n = 631 for all subjects. Prior cardiovascular disease was defined as a history of myocardial infarction and/or Minnosota code 1.1–1.3,
4.1–4.3, 5.1–5.3, or 7.1 on the electrocardiogram, coronary bypass operation and/or angioplasty and/or ankle-brachial pressure
i n d e x <0.90 and/or peripheral arterial bypass or amputation. RR (95% CI) was obtained with Cox regression analyses of cardio-
vascular and all-cause mortality associated with continuous or dichotomous variables after adjustment for age, sex, glucose tol-
erance status (impaired glucose tolerance and type 2 diabetes), except when this was the variable under consideration. *Log-trans-
formed; †>27 vs. £  2 7 k g / m2 for males and >26 vs. £  2 6 k g / m2 for females; ‡<0.9 vs ³  0 . 9 mmol/l; §upper tertile vs. lower tertiles
( > 1 . 5 6 IU/ml for vWF and >2.84 mg/l for CRP levels); albumin-to-creatinine ratio £ 2.0 vs. >2.0 mg/mmol; ¶according to the Cock-
croft-Gault formula; #according to the MDRD formula.
The RR of all-cause mortality associated with sVCAM-1
levels was somewhat less than the RR of cardiovascular mor-
tality (RR per 100 ng/ml sVCAM-1 increase, 1.04 [1.00–1.08];
Ta b l e 3). Further adjustment for risk factors or indicators did
not affect the results (Ta b l e 3 ) .
Additional analyses. To assess whether the association
between cardiovascular mortality and increased levels of
sVCAM-1 varied over time, we performed analyses with dif-
ferent lengths of follow-up duration. The RRs of cardiovas-
cular mortality for increased sVCAM-1 levels were similar over
time (Fig. 2 ) .
To investigate whether the association of sVCAM-1 levels
and risk of cardiovascular mortality among diabetic subjects
was independent of impaired renal function, analyses were
performed after exclusion of subjects with 1) creatinine
clearance <80 ml/min according to the Cockcroft-Gault for-
mula (n = 84) and 2) glomerular filtration rate <80 m l · min– 1 ·
1.73 m– 2 according to the MDRD formula (n = 83). The RRs
of cardiovascular mortality for a 100 ng/ml increase in
sVCAM-1 levels among diabetic subjects did not change
materially (e.g., in model 1 in Ta b l e 3, RR 1.13 [1.06–1.19]
before and 1.12 [0.98–1.27] after exclusion of subjects with
creatinine clearance <80 m l / m i n ) .
To investigate whether the RR of cardiovascular mortality for
sVCAM-1 levels was similar among different risk groups, we per-
formed analyses with interaction terms added (see R E S E A R C H
D E S I G N A N D M E T H O D S). None of the variables associated with
cardiovascular mortality (i.e., age; levels of HDL cholesterol,
v W F, and CRP; and the presence of hypertension, microalbu-
minuria, or cardiovascular disease) showed a significant inter-
action with sVCAM-1 levels (data not shown). Repeating the
analyses for all-cause mortality gave similar results.
Malignancies can influence levels of circulating adhesion
molecules. Levels of sVCAM-1 among subjects who died of
488 DIABETES, VOL. 49, MARCH 2000
sVCAM-1 AND CARDIOVASCULAR MORTALITY
TA B L E 2
sVCAM-1 levels: cross-sectional associations with cardiovascular risk factors or risk indicators
S E ( ) P
Sex (M vs. F) 0 . 0 2 3 0 . 0 1 0 . 0 3
Age (per 1-year increase) 0 . 0 0 2 4 0 . 0 0 1 0 . 0 0 1
Fasting insulin (per 10% increase)* 0 . 0 0 0 2 9 0 . 0 1 1 0 . 0 0 9
Type 2 diabetes (yes vs. no) 0 . 0 5 3 0 . 0 1 3 < 0 . 0 0 0 5
Total cholesterol (per 1.0 mmol/l increase) – 0 . 0 1 8 0 . 0 0 4 < 0 . 0 0 0 5
LDL cholesterol (per 1.0 mmol/l increase) – 0 . 0 1 8 0 . 0 0 5 < 0 . 0 0 0 5
HDL cholesterol (per 1.0 mmol/l increase) – 0 . 0 4 8 0 . 0 1 6 0 . 0 3
vWF (per 1.0 IU/ml increase) 0 . 0 0 0 4 1 < 0 . 0 0 0 5 < 0 . 0 0 0 5
CRP (per 10% increase)* 0 . 0 0 0 1 2 0 . 0 0 0 4 0 . 0 0 4
Homocysteine (per 1.0 µmol/l increase) 0 . 0 0 3 3 0 . 0 0 1 0 . 0 0 1
Hypertension (yes vs. no) 0 . 0 2 2 0 . 0 1 1 0 . 0 4
Current smoking (yes vs. no) – 0 . 0 0 2 3 0 . 0 1 2 0 . 0 4
Microalbuminuria (yes vs. no) 0 . 0 5 3 0 . 0 1 7 0 . 0 0 2
Creatinine clearance (per 1.0 ml/min increase)† – 0 . 0 0 0 8 2 0 . 0 0 0 0 . 0 2
Glomerular filtration rate (per 1.0 ml · m i n– 1 · 1.73 m– 2 i n c r e a s e ) ‡ – 0 . 0 0 2 4 0 . 0 0 0 < 0 . 0 0 0 5
Prior cardiovascular disease (yes vs. no) 0 . 0 2 3 0 . 0 1 2 0 . 0 6
Regression coefficients ( ), standard errors [SE( )], and P values were obtained by linear regression analyses with sVCAM-1 lev-
els (log transformed because of a better fit of the regression model) as dependent and risk factors or indicators as independent vari-
able, all adjusted for age, sex, and glucose tolerance status (unless this was the variable under consideration). Prior cardiovascu-
lar disease was defined as described in the legend to Ta b l e 1; *log-transformed; †according to the Cockcroft-Gault formula; ‡accord-
ing to the MDRD formula.
FIG. 1. Cardiovascular survival (Kaplan-
Meier curves) according to plasma sVCAM-1
in the lowest (417–1,154 ng/ml), middle
( 1 , 1 5 5 – 1 , 4 8 4 ng/ml), and highest (1,485–
5 , 2 6 0 ng/ml) tertiles. *Log-rank test for dif-
ference in survival for different groups;
| censored data. Follow-up (years)
malignancies as compared with those who died of other
causes were not significantly different (1,349 ± 549 vs. 1,388 ±
4 4 4 ng/ml, respectively; P = 0.60). Thirty-nine subjects (36%)
died of cancer. After adjustment for age, sex, and glucose tol-
erance status, sVCAM-1 was not significantly associated with
cancer mortality (RR per 100 ng/ml sVCAM-1 increase, 0.93
[ 0 . 8 5 – 1 . 0 2 ] ) .
D I S C U S S I O N
The most important novel finding of this study is that it
showed sVCAM-1 levels to be significantly associated with risk
of cardiovascular mortality, particularly among type 2 diabetic
subjects. The risk increase did not vary with time. In accor-
dance with previous studies, we showed sVCAM-1 levels to
be significantly associated with male sex, age, fasting insulin
levels, vWF level, the presence of type 2 diabetes, hyperten-
sion, and microalbuminuria, and, inversely, with levels of
total, LDL, and HDL cholesterol and estimates of glomerular
filtration rate (18,20–22,27,37). These variables, however, did
not materially affect the association between sVCAM-1 levels
and risk of cardiovascular mortality (Ta b l e 3). Thus, levels of
sVCAM-1 were significantly and independently associated
with risk of cardiovascular mortality.
The pathophysiological pathway through which sVCAM-1
level is associated with risk of cardiovascular mortality is
u n c l e a r. The most commonly held view is that increased
plasma sVCAM-1 levels indicate increased expression of
membrane-bound VCAM-1 on endothelial and smooth mus-
cle cells and on macrophages, and thus may reflect progres-
sive formation of atherosclerotic lesions (14,17). Alterna-
t i v e l y, increased sVCAM-1 levels might simply be a marker of
an acute phase response, reflecting the progressive low-
grade vessel wall inflammation that plays a pivotal role in the
pathogenesis of atherothrombotic disease (1,38,39). Accord-
i n g l y, several cytokines that can induce an acute phase reac-
tion in response to pro-inflammatory antigens strongly
increased the expression of VCAM-1 on cultured endothelial
cells (40,41). On the other hand, previous clinical studies did
not demonstrate an association of sVCAM-1 levels with lev-
els of acute phase reactants such as CRP (21,27). Although we
did find a moderately strong association between sVCAM-1
and CRP levels, we showed that the association between
sVCAM-1 levels and risk of cardiovascular mortality was
independent of CRP levels, suggesting that sVCAM-1 levels
increase cardiovascular risk through a pathway different
from that of an acute phase response. Third, increased levels
of sVCAM-1 could reflect generalized endothelial d y s f u n c t i o n ,
since we and others showed high sVCAM-1 levels to be asso-
ciated with high vWF levels (18,22,31) and the presence of
microalbuminuria (18), i.e., potential markers of generalized
endothelial dysfunction (42–44). However, we showed
sVCAM-1 levels to be associated with the risk of cardiovas-
cular mortality independent of vWF levels and of microal-
buminuria, which argues against the idea of increased
sVCAM-1 levels being a marker of generalized endothelial dys-
function. However, because endothelial dysfunction is not a
single entity, we cannot exclude the possibility that increased
levels of sVCAM-1 reflect endothelial dysfunction different
from that reflected by increased levels of vWF or the presence
of microalbuminuria. Fourth, increased levels of sVCAM-1 can
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RR of cardiovascular and all-cause mortality associated with sVCAM-1 concentration after adjustment for potentially confounding
risk factors or risk indicators
All-cause 
m o r t a l i t y
Cardiovascular mortality (n = 42) (n = 104)
All subjects Diabetic subjects (all subjects, 
M o d e l Added variables (n = 608) (n = 166) n = 608)
1 Age, sex, glucose tolerance status 1.10 (1.05–1.15) 1.13 (1.07–1.20) 1.04 (1.00–1.08)
2 Model 1 and hypertension, cardiovascular disease, and 1.08 (1.03–1.13) 1.12 (1.06–1.19) 1.04 (1.00–1.08)
low HDL cholesterol level*
3 Model 2 and levels of fasting insulin*, homocysteine, 1.08 (1.02–1.13) 1.11 (1.04–1.19) 1.03 (0.99–1.08)
and total and LDL cholesterol and current smoking
4 Model 2 and microalbuminuria* 1.06 (1.01–1.12) 1.10 (1.03–1.18) 1.03 (0.99–1.07)
5 Model 2 and vWF* 1.07 (1.02–1.12) 1.12 (1.05–1.20) 1.03 (0.99–1.07)
6 Model 2 and CRP* 1.07 (1.02–1.13) 1.13 (1.06–1.20) 1.04 (1.00–1.08)
7 a Model 2 and creatinine clearance* 1.06 (1.01–1.12) 1.11 (1.04–1.18) 1.03 (0.99–1.07)
7 b Model 2 and glomerular filtration rate* 1.06 (1.01–1.11) 1.10 (1.03–1.17) 1.03 (0.99–1.07)
Data are RR (95% CI) of mortality for a 100 ng/ml increase of sVCAM-1 concentration, as obtained with Cox multiple regression analy-
ses. The rationale of Models 1–7 is described in R E S E A R C H D E S I G N A N D M E T H O D S. *Defined as described in Ta b l e 1 .
FIG. 2. RR and 95% CI of cardiovascular mortality associated with a
1 0 0 ng/ml sVCAM-1 increase.
be explained not only by an increased synthesis/shedding
but also by impaired clearance of sVCAM-1 molecules.
Although little is known about the route of elimination of
these molecules, an important role of the kidney has been sug-
gested, since levels of sVCAM-1 were strongly associated
with serum creatinine levels among subjects with chronic
renal failure not receiving dialysis (45,46). Nevertheless, we
found sVCAM-1 levels to be associated with risk of cardio-
vascular mortality independent of estimates of glomerular fil-
tration rate. Thus, although impaired renal function might
cause increased levels of sVCAM-1, this appears not to be the
explanation for the association of sVCAM-1 levels with car-
diovascular risk. Finally, sVCAM-1 itself may have bioactive
properties related to cardiovascular risk. For example, Koch
et al. (47) have recently shown that sVCAM-1 has pro-angio-
genic properties. Taken together, several pathophysiological
mechanisms may explain the association between sVCAM-1
levels and risk of cardiovascular mortality. Our data argue
against the hypotheses of sVCAM-1 levels simply being a
marker of an acute phase response, of endothelial dysfunc-
tion, or of an impaired renal function.
In accordance with previous findings (20,24–29), we
demonstrated levels of sVCAM-1 to be higher among dia-
betic than among nondiabetic subjects, suggesting a
stronger stimulation of VCAM-1 synthesis among diabetic
as compared with nondiabetic subjects. In an environment
with long-standing high glucose concentrations, lipids and
proteins will undergo nonenzymatic glycation and oxida-
tion, resulting in the successive formation of successively
reversible Amadori products (such as GHb) and irre-
versible metabolites, so-called advanced glycated end
products (AGEs) (48,49). However, we, like others
(25,30,50), could not demonstrate a significant association
between levels of sVCAM-1 and GHb. Moreover, AGEs
have been found to increase VCAM-1 expression by acti-
vating its promotor through a nuclear factor- B – l i k e
transcriptional factor (51,52). This suggests that increased
levels of AGEs rather than increased levels of GHb could
be the explanation for the higher levels of sVCAM-1 among
t y p e 2 diabetic as compared with nondiabetic subjects.
These issues need further study.
The present study has several limitations. The levels of
sVCAM-1 were measured once, which may have led to non-
differential misclassification and therefore underestimation
of the RRs associated with mortality. This study was too
small to establish with certainty whether there is an interac-
tion of sVCAM-1 levels and the presence of type 2 diabetes
with regard to cardiovascular risk.
In conclusion, we have shown that the level of sVCAM-1 is
strongly and independently associated with cardiovascular
and all-cause mortality among type 2 diabetic subjects. This
could be of clinical relevance, since therapeutic modalities to
lower VCAM-1 expression have been proposed. Antioxidants
have been shown to inhibit the expression of membrane-
bound VCAM-1 (53), whereas administration of anti–VCAM-1
antibodies has been shown to diminish transendothelial pas-
sage of leukocytes (54). Furthermore, lowering levels of
AGEs by aminoguanidine has been shown to inhibit VCAM-1
expression (55). Thus, therapeutic strategies can lower
VCAM-1 expression and, in parallel, sVCAM-1 levels (16),
which may prevent progression of cardiovascular disease.
These issues, however, need further study.
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